X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aventis Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs MYLAN (US) - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SANOFI INDIA   MYLAN
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
MYLAN
Dec-14
SANOFI INDIA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs4,5604,042-   
Low Rs4,4002,848-   
Sales per share (Unadj.) Rs1,028.51,383.8-  
Earnings per share (Unadj.) Rs129.0166.7-  
Cash flow per share (Unadj.) Rs186.0268.3-  
Dividends per share (Unadj.) Rs68.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs753.6687.9-  
Shares outstanding (eoy) m23.03378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x4.42.5 175.0%   
Avg P/E ratio x34.720.7 168.1%  
P/CF ratio (eoy) x24.112.8 187.6%  
Price / Book Value ratio x5.95.0 118.7%  
Dividend payout %52.70-   
Avg Mkt Cap Rs m103,1741,303,581 7.9%   
No. of employees `0003.625.0 14.5%   
Total wages/salary Rs m3,5920-   
Avg. sales/employee Rs Th6,537.720,942.8 31.2%   
Avg. wages/employee Rs Th991.40-   
Avg. net profit/employee Rs Th819.82,522.9 32.5%   
INCOME DATA
Net Sales Rs m23,686523,570 4.5%  
Other income Rs m708-3,052 -23.2%   
Total revenues Rs m24,394520,519 4.7%   
Gross profit Rs m5,281130,214 4.1%  
Depreciation Rs m1,31338,454 3.4%   
Interest Rs m1522,584 0.1%   
Profit before tax Rs m4,66166,125 7.0%   
Minority Interest Rs m0-271 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6912,781 60.8%   
Profit after tax Rs m2,97063,073 4.7%  
Gross profit margin %22.324.9 89.6%  
Effective tax rate %36.34.2 862.8%   
Net profit margin %12.512.0 104.1%  
BALANCE SHEET DATA
Current assets Rs m15,673460,288 3.4%   
Current liabilities Rs m6,678359,853 1.9%   
Net working cap to sales %38.019.2 198.0%  
Current ratio x2.31.3 183.5%  
Inventory Days Days7678 97.3%  
Debtors Days Days22107 20.8%  
Net fixed assets Rs m8,098121,127 6.7%   
Share capital Rs m23018,515 1.2%   
"Free" reserves Rs m17,0880-   
Net worth Rs m17,356260,266 6.7%   
Long term debt Rs m0388,812 0.0%   
Total assets Rs m25,4001,048,328 2.4%  
Interest coverage x311.73.9 7,936.3%   
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x0.90.5 186.7%   
Return on assets %11.88.2 143.8%  
Return on equity %17.124.2 70.6%  
Return on capital %26.913.6 197.7%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Net fx Rs m2990-   
CASH FLOW
From Operations Rs m3,22668,824 4.7%  
From Investments Rs m-1,555-54,276 2.9%  
From Financial Activity Rs m-1,818-18,135 10.0%  
Net Cashflow Rs m-147-3,588 4.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 67.82 Rs / USD

Compare SANOFI INDIA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare SANOFI INDIA With: ELDER PHARMA  ALEMBIC PHARMA  TORRENT PHARMA  BIOCON LTD  FULFORD INDIA  



Today's Market

Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)

After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.

Related Views On News

ABBOTT INDIA at All Time High; BSE HEALTHCARE Index Up 0.5% (Market Updates)

Jun 25, 2018 | Updated on Jun 25, 2018

ABBOTT INDIA share price has hit an all time high at Rs 7,550 (up 1.60%). The BSE HEALTHCARE Index is up by 0.49%. Among the top gainers in the BSE HEALTHCARE Index today are ABBOTT INDIA (up 1.60%) and SANOFI INDIA (up 0.37%). The top losers include GSK PHARMA (down 0.04%) and JUBILANT LIFE SCIENCES (down 0.13%).

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jun 25, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS